On Nov 06, major Wall Street analysts update their ratings for $Bruker Corp (BRKR.US)$, with price targets ranging from $69 to $80.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $90 to $80.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $78.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $80 to $75.
Barclays analyst Luke Sergott maintains with a buy rating, and adjusts the target price from $75 to $69.
Wells Fargo analyst Brandon Couillard maintains with a buy rating, and maintains the target price at $75.
Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:
Bruker experienced continued softness in the China market and within the biopharma sector during the quarter, according to an analyst.
The company faced a challenging earnings report amidst a difficult macroeconomic climate. Adjustments to forecasts are being made in light of revised fiscal 2024 targets. Despite the adjustments, there is optimism that the company's strong positioning in multi-omics and materials sciences will enable it to capitalize on the anticipated demand resurgence in the biopharma sector and Chinese market.
Bruker's Q3 outcomes fell short of expectations, and the company has reduced its projections for organic sales growth for fiscal 2024, attributing this adjustment to a slower rebound in China and emerging biopharma sectors. According to the analyst, this recalibration of guidance was not caused by a significant downturn in Q3 markets, but rather by previously optimistic forecasts. Despite the revised guidance, the company's management remains optimistic about prospects for 2025.
The company reported a miss for Q3, but the observed trends in BSI Bookings and the updated guidance could improve the outlook as the company heads into Q4.
The positive aspect of the revised guidance for the second half of the year is that it sets the stage for a recalibration of expectations for 2025, potentially lifting a burden for investors.
Here are the latest investment ratings and price targets for $Bruker Corp (BRKR.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$布魯克 (BRKR.US)$的評級，目標價介於69美元至80美元。
摩根大通分析師Rachel Vatnsdal維持買入評級，並將目標價從90美元下調至80美元。
美銀證券分析師Michael Ryskin維持買入評級，目標價78美元。
花旗分析師Patrick B Donnelly維持買入評級，並將目標價從80美元下調至75美元。
巴克萊銀行分析師Luke Sergott維持買入評級，並將目標價從75美元下調至69美元。
富國集團分析師Brandon Couillard維持買入評級，維持目標價75美元。
此外，綜合報道，$布魯克 (BRKR.US)$近期主要分析師觀點如下：
根據分析師的說法，Bruker在中國市場和生物製藥板塊持續疲軟。
公司在艱難的宏觀經濟環境中面臨着具有挑戰性的盈利報告。鑑於修訂後的2024財年目標，正在調整預測。儘管調整了預測，但人們對公司在多組學和材料科學領域的強勁定位感到樂觀，這將使其能夠抓住生物製藥板塊和中國市場預期復甦的需求。
Bruker的第三季度業績表現不及預期，公司已經調低了對2024財年有機銷售增長的預期，並將這一調整歸因於中國和新興生物製藥板塊復甦較慢。根據分析師的說法，這些引導調整並非由於第三季度市場出現重大下滑，而是由於先前樂觀的預測。儘管調整了指引，公司管理層對2025年的前景仍然持樂觀態度。
公司報告了第三季度的遺漏，但在BSI預訂的趨勢和更新後的指引可能改善前景的情況下，公司將進入第四季度。
對於年度下半年的修訂指引的積極方面在於，爲2025年的預期重新調整設定了舞臺，潛在地減輕了投資者的負擔。
以下爲今日6位分析師對$布魯克 (BRKR.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
